Clinical trials: Prostate Neoplasm
Cancer Related Fatigue
Body Mind Training Project
Aim 1: Assess the feasibility, safety and efficacy of a Qigong intervention in elderly prostate cancer survivors. Describe participation, retention, and adherence rates and assess reasons for participation, attrition, and…
- Trial name
- NCT01564394
- Testing
- Qigong, Non-aerobic stretching
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Utah
Prostate Cancer, Cholelithiases
A Prospective, Single-center, Single-arm, Pivotal Trial of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System
The goal of this clinical trial is to test the safety and effectiveness of the Medtronic Hugo™ RAS System in patients undergoing a prostatectomy or a cholecystectomy.
- Conditions
- Prostate Cancer, Cholelithiases, Cholecystitis, Gallbladder Polyp
- Trial name
- NCT05715827
- Testing
- RAS prostatectomy and RAS cholecystectomy
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Medtronic - MITG
Prostate Cancer
MRI Guided Prostate Cancer Focal Laser Ablation
The study is a prospective, single-arm, non-randomized, unblinded trial to determine the safety and efficacy of MRI guided focal laser ablation of localized low and intermediate risk prostate cancer.
- Trial name
- NCT03634579
- Testing
- MRI Guided Focal Laser Interstitial Thermal Ablation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Prostate Cancer
High Resolution MRI Study for Prostate Cancer
This high resolution MRI (hrMRI), along with stand MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
- Trial name
- NCT03292874
- Testing
- high resolution MRI (hrMRI)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Some patients with prostate cancer benefit from androgen deprivation therapy which reduces levels of testosterone. Leuprolide is a synthetic Luteinizing hormone releasing hormone (LHRH) analogue which upon administration can…
- Trial name
- NCT01415960
- Testing
- Leuprolide acetate 22.5 mg depot, GP-Pharm SA
- Where
- 25 sites in United States
- Volunteers
- 163 people
- Sponsor
- GP-Pharm
mCRPC
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
- Trial name
- TALAPRO-2 (NCT03395197)
- Testing
- Talazoparib with enzalutamide
- Where
- 370 sites in United States, Argentina and 24 more
- Volunteers
- 1,054 people
- Sponsor
- Pfizer
Cervical Cancer, Endometrial Cancer
A Study of Patients Receiving High-Dose Rate Brachytherapy
Background: One standard way of giving radiation is to combine external beam treatments with internal brachytherapy treatments, which involve short-range radiation therapy that gives a high dose of radiation directly to a cancer…
- Conditions
- Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer
- Trial name
- NCT00924027
- Testing
- High Dose Radiation (HDR) Brachytherapy, MRI, CT
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer, Lung Cancer
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
The hypotheses of the study are as follows: Mass-based inverse optimization in radiotherapy treatment planning will result in a reduction of normal tissue and organs at risk (OAR) doses for desired prescription therapeutic doses…
- Conditions
- Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT02663817
- Testing
- CT Scan
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Miami
Prostate Cancer
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
- Trial name
- NCT00860158
- Testing
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Noah Hahn, M.D.
Prostate Cancer, Bone Metastases
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Trial name
- NCT02582749
- Testing
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Ajjai Alva, MD
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer
Study to Evaluate CCS1477 in Advanced Tumours
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT03568656
- Testing
- CCS1477, Abiraterone acetate, Enzalutamide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 219 people
- Sponsor
- CellCentric Ltd.
Prostatic Neoplasms, Prostate Cancer
Fulvestrant in Hormone Refractory Prostate Cancer
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have…
- Trial name
- NCT00476645
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Prostate Cancer
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
The overall objective of this Early Phase Clinical Trial is to begin defining the accuracy of 68Ga-PSMA-11 for detecting the location and size of clinically significant prostate cancer lesions in low and intermediate risk…
- Trial name
- NCT03429244
- Testing
- 68Ga-PSMA-11 PET-MRI
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Prostate Cancer
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
The purpose of this study is to assess for changes in a patient's overall energy level and well-being (quality of life) after 8 weeks of dietary intervention.
- Trial name
- NCT01083771
- Testing
- Olive Oil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Brown University
ATM Gene Mutation, BRCA1 Gene Mutation
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation
- Trial name
- NCT04030559
- Testing
- Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Davis
Metastatic Castration-resistant Prostate Cancer
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer…
- Trial name
- NCT04740034
- Testing
- AMG 340
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Amgen
Cancer, Prostate Cancer
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT02325557
- Testing
- ADXS31-142, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Advaxis, Inc.
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center